Intracranial Cryptococcoma-Clinicopathologic Correlation and Surgical Outcome: A Single-Institution Experience

World Neurosurg. 2018 Jul:115:e349-e359. doi: 10.1016/j.wneu.2018.04.056. Epub 2018 Apr 17.

Abstract

Objective: To describe clinical characteristics of patients with intracranial cryptococcoma, clinicopathologic findings, and outcomes after surgery.

Materials and methods: Clinical data were collected from hospital case records, and pathologic confirmation was done by a neuropathologist. Clinical details, imaging features, and treatment modalities were evaluated and correlated with outcomes based on regular follow-up.

Results: This case series included 5 cases of histology- and culture-proven intracranial cryptococcoma. Three patients (60%) were aged between the 3rd and 5th decades. Three cases were supratentorial in location, and 2 were in the posterior fossa. One patient presented with seizures. Three patients (60%) presented with fever. Three patients (60%) had papilledema, and 4 (80%) had signs of meningeal irritation. Four patients (80%) were immunocompetent. Only 1 patient was immunocompromised. All lesions were peripherally enhancing on computed tomography. Four of 5 patients underwent surgical decompression without any residue. Only 1 patient underwent stereotactic biopsy. All patients received antifungal therapy. One patient who was immunocompromised developed multiorgan failure and died after 2 months after surgery (20%). Of 5 cases, 4 (80%) had a good outcome with a mean follow-up of 5 years.

Conclusions: Cryptococcus gattii is a rarer species implicated in intracranial cryptococcoma that is seen along with the more common Cryptococcus neoformans. Early diagnosis and surgical decompression followed by intravenous amphotericin B therapy for at least 6 weeks and concomitant therapy with fluconazole for prolonged periods may reduce morbidity and mortality.

Keywords: Amphotericin B; Cryptococcus gattii; Cryptococcus neoformans; Immunocompromised; Intracranial cryptococcoma.

MeSH terms

  • Adult
  • Aged
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use*
  • Cryptococcus gattii / drug effects
  • Female
  • Fluconazole / pharmacology
  • Humans
  • Immunocompromised Host / drug effects*
  • Male
  • Meningitis, Cryptococcal / diagnosis
  • Meningitis, Cryptococcal / drug therapy
  • Meningitis, Cryptococcal / surgery*
  • Middle Aged
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Amphotericin B
  • Fluconazole